MedTrace Logo

Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas

NCT03029104 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2228

Last updated 2022-01-12

Study results available
· View outcomes & findings →

Summary

This study will assess changes in visual acuity and corneal symmetry after corneal collagen cross-linking (CXL) of asymmetric corneas.

Conditions

  • Keratoconus
  • Corneal Diseases
  • Eye Diseases
  • Photosensitizing Agents

Interventions

COMBINATION_PRODUCT

CXLO Corneal Strengthening Solution and UVA Illumination Device

CXLO Corneal Strengthening Solution

Sponsors & Collaborators

  • Cxlusa

    lead INDUSTRY

Principal Investigators

  • Gregg J Berdy, MD, FACS · Ophthalmology Associates, St. Louis, MO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-21
Primary Completion
2020-12-27
Completion
2020-12-27
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03029104 on ClinicalTrials.gov